Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 11Active not recruiting 4Terminated 3Withdrawn 2Unknown 1Suspended 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 8Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasms 4Colorectal Neoplasms 4Stomach Neoplasms 3Prostatic Neoplasms 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Carcinoma, Basal Cell 3Barrett Esophagus 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Lung Neoplasms 2Liver Neoplasms 2Inflammatory Bowel Diseases 2Colonic Neoplasms 2Breast Neoplasms, Male 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Tuberculosis 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Diseases 1Squamous Intraepithelial Lesions 1Small Cell Lung Carcinoma 1

Interventions

Carboplatin 15camrelizumab 11Capecitabine 11130-nm albumin-bound paclitaxel 10pembrolizumab 8eribulin 8Paclitaxel 8Cyclophosphamide 8Epirubicin 7Gemcitabine 6Cisplatin 6tislelizumab 5apatinib 5atezolizumab 4anlotinib 4Taxes 4Nivolumab 4Docetaxel 4Bevacizumab 4toripalimab 3Vinorelbine 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Doxorubicin 3Albumin-Bound Paclitaxel 3talazoparib 2spartalizumab 2olaparib 2fluzoparib 2famitinib 2Zoledronic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Triple Negative Breast Neoplasms × Biopsy × Clear all
NCT01372579 2019-06-07

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Northwestern University

Phase 2 Unknown
30 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡